Do malaria vaccines lower the risk of invasive non-typhoidal Salmonella in young children?

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an observational, test-negative case-control study built on ongoing fever surveillance in the Kisantu Health Zone. Children and other patients who present to participating healthcare facilities with fever are tested for malaria (mRDT, microscopy, PCR) and invasive non-typhoidal Salmonella (automated blood culture). Vaccination status for R21/Matrix-M is confirmed using EPI cards, a local vaccination registry, or home visits where needed, and analyses compare vaccination rates in iNTS-positive versus iNTS-negative patients. All participants with confirmed infections receive treatment per national guidelines.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Patients of all ages currently living in the catchment area of the health center presenting to healthcare facility with objective fever of at least 38.0°C tympanic or 37.5 °C axillary OR
2. Patients of all ages currently living in the catchment area of the health center presenting to healthcare facility with reported fever ≥3 consecutive days within 7 days of presentation

Where it's running

• Institut National de Recherche Biomedicale (INRB)
  Kinshasa, Democratic Republic of the Congo Recruiting

Study contacts

• Principal investigator: Octavie Lunguya — Institut National de Recherche Biomedicale
• Study coordinator: Birkneh Tadesse, MD, PHD
• Email: Birkneh.Tadesse@ivi.int
• Phone: +821098041348

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Lotilaner safety and blood activity in healthy adults in Mali

  This Phase 1b study tests if a single dose of lotilaner is safe, tolerable, and shows mosquito-killing activity in healthy adults living in Mali.

  Recruiting Phase 1 Medicines for Malaria Venture · Bamako · NCT07758985

• See if the R21/Matrix-M malaria vaccine works in real-world settings for kids under 5

  This study tests how well the R21/Matrix-M vaccine protects children under 5 in Burkina Faso and Uganda when used in typical clinical care.

  Recruiting at 12 sites Clinton Health Access Initiative Inc. · Boromo, Boucle Mouhoun and 20 other locations · NCT07749911

• Community spread of multiple infectious diseases in Cambodia from a One Health perspective

  This project will test how common and connected dengue, chikungunya, Zika, Japanese encephalitis, and West Nile infections are among people, animals, and the environment across Cambodia.

  Recruiting Institut Pasteur du Cambodge · Phnom Penh, Phnom Penh · NCT07358910

• Lower-dose and alternate-schedule RTS,S malaria vaccine for young children

  This project will test if smaller doses and different schedules of the RTS,S malaria vaccine are safe and help build immunity in healthy children aged 5 to 60 months who live where malaria is common.

  Recruiting at 2 sites Phase 2 GlaxoSmithKline · Kigali and 1 other locations · NCT07036159

• Optimizing malaria and HIV treatment for children in Busia and Kampala

  We will test whether dolutegravir affects growth and how it interacts with common malaria medicines in children with and without HIV, following them for two years in Busia and Kampala.

  Recruiting at 2 sites Phase 4 Yale University · Kampala and 1 other locations · NCT06967519

• R21 malaria vaccine plus seasonal malaria chemoprevention for young children in West Africa

  This project will test whether giving the R21 malaria vaccine together with seasonal malaria chemoprevention prevents clinical malaria in young children in Burkina Faso and Mali.

  Recruiting at 2 sites Phase 4 Epicentre · Ouagadougou and 1 other locations · NCT06860178

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.